| 000 | 01315 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515211944.0 | ||
| 264 | 0 | _c20100407 | |
| 008 | 201004s 0 0 eng d | ||
| 022 | _a0031-7144 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aUesawa, Y | |
| 245 | 0 | 0 |
_aPrediction models for feverishness developed during interferon therapy of chronic hepatitis C patients. _h[electronic resource] |
| 260 |
_bDie Pharmazie _cFeb 2010 |
||
| 300 |
_a114-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 |
_aBody Temperature _xdrug effects |
| 650 | 0 | 4 | _aData Interpretation, Statistical |
| 650 | 0 | 4 | _aExcipients |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFever _xchemically induced |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferons _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 | _aPolyethylene Glycols |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 |
_aRibavirin _xadministration & dosage |
| 700 | 1 | _aMotege, E | |
| 700 | 1 | _aDai, Y | |
| 700 | 1 | _aIshii, K | |
| 700 | 1 | _aMohri, K | |
| 773 | 0 |
_tDie Pharmazie _gvol. 65 _gno. 2 _gp. 114-6 |
|
| 999 |
_c19591884 _d19591884 |
||